Thermo Fisher Wins FDA Nod for NGS-Based Companion Diagnostic Supporting New NSCLC Therapy
Thermo Fisher Scientific Secures FDA Approval for NGS-Based Companion Diagnostic to Support New HER2-Targeted NSCLC Therapy Thermo Fisher Scientific Inc. (NYSE: TMO), the global leader in serving science, has announced…
Cadrenal Therapeutics Announces Q2 2025 Financial Results and Corporate Progress Update
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results, Advances Tecarfarin Clinical Development, and Strengthens Strategic Position in Anticoagulation Market Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company dedicated to developing…
Tahoe Therapeutics Secures $30M to Develop World’s Largest Human Cell AI Training Dataset
Tahoe Therapeutics Secures $30 Million to Build the World’s Largest Dataset for Training AI-Powered Human Cell Models, Aiming to Transform Precision Medicine Tahoe Therapeutics, a biotechnology company at the intersection…
Stoke, Biogen Dose First Patient in Phase 3 EMPEROR Trial for Dravet Therapy
Stoke Therapeutics and Biogen Dose First Patient in Pivotal Phase 3 EMPEROR Study of Zorevunersen, an Investigational Disease-Modifying Therapy for Dravet Syndrome Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company…
Newron Highlights Preclinical Data Showing Evenamide’s Potential in Schizophrenia
Newron Announces Landmark Preclinical Study Supporting Evenamide’s Potential to Transform Schizophrenia Treatment Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for…
Rocket Pharmaceuticals Announces Q2 2025 Financial Results and Key Business Milestones
Rocket Pharmaceuticals Announces Second Quarter 2025 Results, Reshapes Strategic Focus Around Cardiovascular Gene Therapy Platform, and Advances Late-Stage Pipeline Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company…
C2N Expands Worldwide Footprint with Addition of Six New Global Partners
C2N Diagnostics Accelerates Global Expansion with Six New International Partnerships to Broaden Access to Alzheimer’s Blood Testing C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company committed to its mission of…
BioMendics Begins TAMES-02 Trial for New EBS Therapy
BioMendics Launches Landmark TAMES-02 Clinical Trial to Advance First-in-Class Therapy for Epidermolysis Bullosa Simplex BioMendics, a clinical-stage biopharmaceutical company specializing in the development of novel therapies for rare dermatologic conditions,…
CGT Global Welcomes Dr. Andrew Branagan to Board of Advisors to Strengthen Cell and Gene Therapy Leadership
CGT Global Strengthens Advisory Leadership with Appointment of Dr. Andrew Branagan, Enhancing Expertise in Hematologic Malignancies and Advanced Cell and Gene Therapy Development CGT Global, a biotechnology innovator dedicated to…
Melinta Therapeutics Acquired by CorMedix, Highlighting Portfolio Strength and Leadership
Melinta Therapeutics to Be Acquired by CorMedix in $300 Million Deal, Marking a Major Milestone in the Acute Care Pharmaceutical Sector Melinta Therapeutics, LLC (“Melinta”), a leading commercial-stage pharmaceutical company…
Precision BioSciences Announces Q2 2025 Financial Results and Business Highlights
Precision BioSciences Reports Second Quarter 2025 Financial Results, Highlights Strong Clinical Progress in Gene Editing Programs, and Extends Cash Runway Into 2027 Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology…
Palleon Begins Phase 2 Trial of E-602 for Active Glomerulonephritis
Palleon Pharmaceuticals Initiates Phase 2 Clinical Trial of E-602 (HLX79) in Combination with HANLIKANG (Rituximab Biosimilar) for Patients with Active Glomerulonephritis Palleon Pharmaceuticals, a biotechnology company at the forefront of…